---
title: "This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275771513.md"
description: "Top Wall Street analysts have downgraded several stocks. Baird's Mike Polark downgraded Inspire Medical Systems (NYSE:INSP) from Outperform to Neutral, lowering the price target from $130 to $74. JP Morgan's Jeffrey Zekauskas downgraded Valvoline (NYSE:VVV) from Neutral to Underweight, raising the price target from $30 to $35. Wells Fargo's Eva Fortea Verdejo downgraded Arcus Biosciences (NYSE:RCUS) from Overweight to Equal-Weight, cutting the price target from $30 to $23. Jason Haas also downgraded Rollins (NYSE:ROL) from Overweight to Equal-Weight, reducing the price target from $68 to $56."
datetime: "2026-02-12T14:21:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275771513.md)
  - [en](https://longbridge.com/en/news/275771513.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275771513.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275771513.md) | [繁體中文](https://longbridge.com/zh-HK/news/275771513.md)


# This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   Baird analyst Mike Polark downgraded **Inspire Medical Systems Inc** (NYSE:INSP) from Outperform to Neutral and cut the price target from $130 to $74. Inspire Medical shares closed at $68.21 on Wednesday. See how other analysts view this stock.
-   JP Morgan analyst Jeffrey Zekauskas downgraded **Valvoline Inc** (NYSE:VVV) from Neutral to Underweight and raised the price target from $30 to $35. Valvoline shares closed at $38.87 on Wednesday. See how other analysts view this stock.
-   Wells Fargo analyst Eva Fortea Verdejo downgraded **Arcus Biosciences Inc** (NYSE:RCUS) from Overweight to Equal-Weight and slashed the price target from $30 to $23. Arcus Biosciences shares closed at $21.36 on Wednesday. See how other analysts view this stock.
-   Wells Fargo analyst Jason Haas downgraded **Rollins Inc** (NYSE:ROL) from Overweight to Equal-Weight and cut the price target from $68 to $56. Rollins shares closed at $65.60 on Wednesday. See how other analysts view this stock.

Considering buying INSP stock? Here’s what analysts think:

Photo via Shutterstock

### Related Stocks

- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [Arcus Biosciences, Inc. (RCUS.US)](https://longbridge.com/en/quote/RCUS.US.md)
- [Inspire Medical Systems, Inc. (INSP.US)](https://longbridge.com/en/quote/INSP.US.md)
- [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Rollins, Inc. (ROL.US)](https://longbridge.com/en/quote/ROL.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)
- [Valvoline Inc. (VVV.US)](https://longbridge.com/en/quote/VVV.US.md)

## Related News & Research

- [Aristotle Capital Boston LLC Acquires 79,627 Shares of Valvoline $VVV](https://longbridge.com/en/news/279146075.md)
- [Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of "Moderate Buy" from Analysts](https://longbridge.com/en/news/279226861.md)
- [BUZZ-MiniMed rises as FDA clears smartphone‑controlled insulin pump](https://longbridge.com/en/news/279614092.md)
- [Capricor Theraputics Q4 revenue falls to zero, net loss widens](https://longbridge.com/en/news/278939139.md)
- [BUZZ-CytomX retreats ahead of planned $250 mln equity raise after promising cancer drug data](https://longbridge.com/en/news/279463333.md)